Article History

Historical News Related to Your Article
La Rosa Regains Compliance with Nasdaq

La Rosa Regains Compliance with NasdaqCelebration, FL, April 19, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that on April 18, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (Nasdaq), informing the Company that it has regained compliance with Nasdaq Continue Listing Rules by satisfying Nasdaq’s Equity Standard under Listing Rule 5550(b). [...]GlobeNewswire - US19 Apr 2024

Gaxos.ai Regains Compliance with Nasdaq Listing RequirementsRoseland, NJ, March 26, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. [...]GlobeNewswire - US26 Mar 2024

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsSEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). [...]GlobeNewswire - US18 Mar 2024

Avenue Therapeutics Receives Positive Listing Determination from NasdaqMIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1. [...]GlobeNewswire - US15 Mar 2024

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementPALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). [...]GlobeNewswire - US14 Mar 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire - US05 Mar 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units (RSUs) covering an aggregate of 11,300 shares, of BioCryst common stock. [...]GlobeNewswire - US05 Mar 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy OfficerBEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Executive Chairman, Pravin U. [...]GlobeNewswire - US22 Feb 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (Iovance or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees. [...]GlobeNewswire - US16 Feb 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). [...]GlobeNewswire - US16 Feb 2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the compensation committee of BridgeBio’s board of directors granted thirty-five new employees restricted stock units for an aggregate of 123,838 shares of the Company’s common stock. [...]GlobeNewswire - US06 Feb 2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 59,750 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan. [...]GlobeNewswire - US02 Feb 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 32,100 shares, and restricted stock units (RSUs) covering an aggregate of 21,450 shares, of BioCryst common stock. [...]GlobeNewswire - US02 Feb 2024

Agrify Receives Positive Nasdaq Listing DeterminationTROY, Michigan, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through April 15, 2024, to evidence compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires listed companies to have a stockholders’ equity of at least $2. [...]GlobeNewswire - US31 Jan 2024

Agrify Receives Positive Nasdaq Listing DeterminationAgrify Receives Positive Nasdaq Listing DeterminationGlobeNewswire - US31 Jan 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (Iovance or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on January 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 51,375 shares of Iovance’s common stock to six new non-executive employees. [...]GlobeNewswire - US19 Jan 2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on January 08, 2024, the compensation committee of BridgeBio’s board of directors granted twenty five new employees restricted stock units for an aggregate of 66,963 shares of the Company’s common stock. [...]GlobeNewswire - US10 Jan 2024

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M. [...]GlobeNewswire - US29 Dec 2023

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on December 21, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 44,175 shares of Iovance’s common stock to four new non-executive employees. [...]GlobeNewswire - US22 Dec 2023

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire - US15 Dec 2023

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U. [...]GlobeNewswire - US12 Dec 2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the compensation committee of BridgeBio’s board of directors granted thirty new employees restricted stock units for an aggregate of 147,373 shares of the Company’s common stock. [...]GlobeNewswire - US08 Dec 2023

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to ConditionsBOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company’s request to continue its listing on The Nasdaq Stock Market (“Nasdaq” or the “Exchange”. [...]GlobeNewswire - US27 Oct 2023

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on October 20, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 48,300 shares of Iovance’s common stock to ten new non-executive employees. [...]GlobeNewswire - US20 Oct 2023

ASP Isotopes Announces Private Placement of Approximately $8 Million Shares of Common Stock, Priced “At the Market” Under NASDAQ RulesInvestors Include Well Known Uranium and Critical Resource Investor Tees River, through its Tees River Critical Resources Fund and Members of the Board Investors Include Well Known Uranium and Critical Resource Investor Tees River, through its Tees River Critical Resources Fund and Members of the Bo [. [...]GlobeNewswire - US09 Oct 2023

CalAmp Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- CalAmp (Nasdaq: CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced that on October 5, 2023, the Human Capital Committee of CalAmp’s Board of Directors granted inducement restricted stock unit awards covering 252,240 shares of CalAmp common stock to four new non-executive employees. [...]GlobeNewswire - US06 Oct 2023

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. [...]GlobeNewswire - US06 Oct 2023

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 2, 2023 (the “Grant Date”), ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2023. [...]GlobeNewswire - US06 Oct 2023

Rocky Mountain Chocolate Factory Appoints Scott Ouellet as Senior Vice President of Manufacturing and Supply Chain and Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)DURANGO, Colo., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we” or “RMCF”), an international franchisor and producer of premium chocolates and other confectionary products, announced today that global snack industry veteran Scott Ouellet has been appointed to the role of Senior Vice President, Manufacturing and Supply Chain, effective September 18, 2023. [...]GlobeNewswire - US22 Sep 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. [...]GlobeNewswire - US15 Sep 2023

Clever Leaves Regains Compliance with Nasdaq Minimum Bid Price RequirementTOCANCIPÁ, Colombia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on September 11, 2023 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the Rule) for continued listing on the Nasdaq Capital Market. [...]GlobeNewswire - US13 Sep 2023

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsCHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). [...]GlobeNewswire - US23 Aug 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 42,840 restricted stock units of the company’s common stock to 18 newly hired non-executive officers of the company. [...]GlobeNewswire - US18 Aug 2023

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on August 17, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 107,250 shares of Iovance’s common stock to eight new non-executive employees. [...]GlobeNewswire - US18 Aug 2023

Moxian Regains Compliance with NASDAQ Minimum Bid Price RequirementBeijing, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moxian (BVI) Inc (“Moxian” or the “Company”) (NASDAQ: MOXC), a company engaged in bitcoin mining and related services in the United States, announced today on August 14, 2023, it received notification from The Nasdaq Stock Market LLC (“NASDAQ”) confirming the Company has regained compliance with NASDAQ’s minimum bid price requirement under Listing Rule 5550(a)(2). [...]GlobeNewswire - US15 Aug 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities RequirementLEXINGTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market. [...]GlobeNewswire - US09 Aug 2023

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public FloatCommon Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023 Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023GlobeNewswire - US04 Aug 2023

Versus Systems Granted Additional 180 Calendar Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementLOS ANGELES, July 26, 2023 (GLOBE NEWSWIRE) -- Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ: VS) announced that it has received an additional extension of 180 calendar days from The Nasdaq Stock Market LLC (Nasdaq) to regain compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement) for continued listing on the Nasdaq Capital Market. [...]GlobeNewswire - US26 Jul 2023

Blue Star Foods Regains Compliance with NASDAQ Minimum Bid Price RequirementMiami, FL, July 13, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus on Recirculatory Aquaculture Systems (RAS), today announced that it has received a formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Blue Star Foods has regained compliance with the $1. [...]GlobeNewswire - US13 Jul 2023

Acri Capital Acquisition Corporation Announces Transfer to Nasdaq Capital MarketAustin, Texas, July 07, 2023 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that the Nasdaq Stock Market LLC has approved the Company’s application to list its common stock, units, and warrants on the Nasdaq Capital Market. [...]GlobeNewswire - US07 Jul 2023

Phunware Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)AUSTIN, Texas, July 07, 2023 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN) (the “Company”), the pioneer of Location Based SaaS that offers the only fully integrated enterprise cloud platform for mobile that enables brands to engage, manage and monetize anyone anywhere, today announced that it made an inducement grant to Mr. [...]GlobeNewswire - US07 Jul 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to a new employee. [...]GlobeNewswire - US07 Jul 2023

Vislink Technologies, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Mt. Olive, NJ, July 07, 2023 (GLOBE NEWSWIRE) -- Vislink Technologies, Inc. (“Vislink” or the “Company”) (Nasdaq: VISL) announced today that on July 5, 2023, Steven Teese was granted a time-based and performance-based award of 25,000 restricted stock units (“RSUs”) of the Company outside of the Company’s existing equity compensation plans, in connection with Mr. [...]GlobeNewswire - US07 Jul 2023

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesCLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses.GlobeNewswire - US07 Jul 2023

The Sustainable Green Team, LTD. Announces Engagement of First Level Capital For Business Advisory and Investor Relations Services in Preparation of Proposed Uplisting To Nasdaq ExchangeOrlando, FL, June 28, 2023 (GLOBE NEWSWIRE) -- The Sustainable Green Team, LTD. (OTCQX: SGTM) (“SGTM” or the “Company”), a provider of environmentally conscious solutions in the arbor care, disposal, and recycling industries, announced today that it has hired First Level Capital LLC, a full-service advisory and investor relations firm (the Firm or “First level Capital”). [...]GlobeNewswire - US28 Jun 2023

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsPASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. [...]GlobeNewswire - US23 Jun 2023

Roper Technologies announces move to NasdaqSARASOTA, Fla., June 22, 2023 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (NYSE: ROP) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange. The Company expects to begin trading as a Nasdaq-listed company on July 6, 2023 and will continue to trade under the symbol “ROP. [...]GlobeNewswire - US22 Jun 2023

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. [...]GlobeNewswire - US10 Jun 2023

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementCompany continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 studyGlobeNewswire - US06 Jun 2023

Seaport Global Acquisition II Corp. and American Battery Materials Announce Definitive Business Combination Agreement to Create Nasdaq Listed CompanyNEW YORK and GREENWICH, Conn., June 02, 2023 (GLOBE NEWSWIRE) -- Seaport Global Acquisition II Corp. (NASDAQ: SGII) (“SGII”), a publicly-listed special purpose acquisition company, and American Battery Materials, Inc. (OTC Pink: BLTH) (“ABM” or the “Company”), a minerals exploration and development company focused on environmentally friendly direct lithium extraction (“DLE”), today announced that they have entered into a definitive merger agreement for a business combination (the “Proposed Business Combination”) that will result in ABM becoming a wholly-owned subsidiary of SGII. [...]GlobeNewswire - US02 Jun 2023

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock, at a purchase price of $3. [...]GlobeNewswire - US23 May 2023

GoLogiq in Late-Stage Discussions for Business Combination with Nasdaq Listed CompanyNEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- GoLogiq, Inc. (OTC:GOLQ), a U.S.-based global provider of fintech and consumer data analytics, announced that the company has advanced to late stage discussions and has signed a non-binding letter of intent with a Nasdaq listed company for a planned business combination. [...]GlobeNewswire - US18 May 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees. [...]GlobeNewswire - US05 May 2023

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. [...]GlobeNewswire - US05 May 2023

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., May 05, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 89,559 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees. [...]GlobeNewswire - US05 May 2023

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingCARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today reports that on April 20, 2023, it received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) relating to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) as required under Section 5250(c) of Nasdaq Rules regarding the Qualification, Listing and Delisting of Companies (the “Nasdaq Listing Rules”). [...]GlobeNewswire - US21 Apr 2023

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesSEATTLE, April 20, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4. [...]GlobeNewswire - US20 Apr 2023

Surgalign Announces Receipt of Nasdaq Deficiency Notice and Intends to Submit Plan to Regain ComplianceDEERFIELD, Ill., April 13, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on April 10, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the $10 million minimum stockholders’ equity requirement for continued listing on the NASDAQ Global Select Market under Nasdaq Listing Rule 5450(b)(1)(A). [...]GlobeNewswire - US13 Apr 2023

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesBOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million. Investors in the private placement were Cocrystal Director and co-founder Phillip Frost, M. [...]GlobeNewswire - US10 Apr 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees. [...]GlobeNewswire - US07 Apr 2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of directors granted five new employees restricted stock units for an aggregate of 25,900 shares of the Company’s common stock. [...]GlobeNewswire - US07 Apr 2023

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations OfficerBOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the grant of an inducement award outside of the Company’s 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph. [...]GlobeNewswire - US04 Apr 2023

Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares of its common stock at a purchase price of $3. [...]GlobeNewswire - US31 Mar 2023

Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QBaltimore, March 24, 2023 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) on March 21, 2023 (i) notifying the Company that it is not in compliance with the periodic filing requirements for continued listing because the Company’s Form 10-Q for the fiscal quarter ended January 31, 2023 was not filed with the Securities and Exchange Commission (the “SEC”) by the required due date of March 17, 2023 (“Additional Delinquency”), which is an additional basis for delisting the Company’s securities from the Nasdaq and (ii) indicating that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Company’s continued listing on the Nasdaq at its hearing before the Panel scheduled for Thursday, March 30, 2023 (“Hearing”). [...]GlobeNewswire - US24 Mar 2023

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools Inc. [...]GlobeNewswire - US22 Mar 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 7,130 shares of common stock of the company and 5,885 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company. [...]GlobeNewswire - US21 Mar 2023

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsLOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. [...]GlobeNewswire - US13 Mar 2023

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units (RSUs) covering an aggregate of 51,300 shares, of BioCryst common stock. [...]GlobeNewswire - US02 Mar 2023

BioSig Regains Compliance With All Nasdaq Listing StandardsWestport, CT, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, announced today that it has received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq because the bid price of the Company’s common stock closed at or above $1. [...]GlobeNewswire - US22 Feb 2023

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (“Scilex”) previously held by Sorrento. [...]GlobeNewswire - US19 Feb 2023

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleCompany Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 MonthsGlobeNewswire - US15 Feb 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees. [...]GlobeNewswire - US10 Feb 2023

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on February 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,000 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc. [...]GlobeNewswire - US10 Feb 2023

Science 37 Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. [...]GlobeNewswire - US10 Feb 2023

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 20 newly-hired employees stock options to purchase an aggregate of 287,200 shares, and restricted stock units (RSUs) covering an aggregate of 101,700 shares, of BioCryst common stock. [...]GlobeNewswire - US06 Feb 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3. [...]GlobeNewswire - US24 Jan 2023

Vivos Therapeutics Regains Compliance with Nasdaq Listing RequirementsLITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) informing Vivos it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). [...]GlobeNewswire - US20 Jan 2023

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022. [...]GlobeNewswire - US30 Dec 2022

Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into securities purchase agreements with existing institutional and accredited investors for the purchase and sale of 28,460,831 shares of common stock at a purchase price of $0. [...]GlobeNewswire - US23 Dec 2022

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. [...]GlobeNewswire - US20 Dec 2022

Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain ComplianceWARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1. [...]GlobeNewswire - US05 Dec 2022

Aileron Therapeutics Regains Compliance with Nasdaq Listing RequirementsBOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1. [...]GlobeNewswire - US30 Nov 2022

Republic First Bancorp, Inc. Receives Notice of Additional Filing Delinquency From NasdaqPHILADELPHIA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Republic First Bancorp, Inc. (NASDAQ: FRBK) (the “Company”), the holding company for Republic First Bank d/b/a Republic Bank, announced that on November 14, 2022, the Company received written notification that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 with the Securities and Exchange Commission (the “Commission”), the Company does not comply with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all periodic reports with the Commission. [...]GlobeNewswire - US18 Nov 2022

Aravive Regains Compliance with Nasdaq Minimum Bid Price RequirementHOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). [...]GlobeNewswire - US16 Nov 2022

SOLAREDGE TECHNOLOGIES, INC. (NASDAQ: SEDG) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against SolarEdge Technologies, Inc. (NASDAQ: SEDG)Did you lose money on investments in SolarEdge Technologies? If so, please visit SolarEdge Technologies, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.GlobeNewswire - US04 Nov 2022

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-KLOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the Company) received a notice (the Notice) from The Nasdaq Stock Market LLC (Nasdaq) stating that because the Company has not yet filed its Form 10-K, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the SEC). [...]GlobeNewswire - US21 Oct 2022

Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq RulesFLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive agreements with several institutional investors (the “Investors”) for the purchase of 3,275,153 shares of the company’s common stock at $2. [...]GlobeNewswire - US21 Oct 2022

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 43 individuals hired by Sarepta in September 2022. [...]GlobeNewswire - US30 Sep 2022

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needsGlobeNewswire - US14 Sep 2022

P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic ReportHENDERSON, Nev., Aug. 19, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on August 17, 2022 it received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market ( “Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022 (the “Second Quarter Form 10-Q”), its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”) and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the “First Quarter Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”). [...]GlobeNewswire - US19 Aug 2022

Legacy Housing Corporation Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QBEDFORD, Texas, Aug. 12, 2022 (GLOBE NEWSWIRE) -- On August 11, 2022, Legacy Housing Corporation (the Company, NASDAQ: LEGH) received a notice from The Nasdaq Stock Market LLC (Nasdaq) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the Form 10-Q2) the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. [...]GlobeNewswire - US12 Aug 2022

FedNat Receives Nasdaq Notification of Non-Compliance With Listing Rule 5250(c)(1)SUNRISE, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- FedNat Holding Company (Nasdaq: FNHC), a regional insurance holding company, today announced that on April 1, 2022, it received a letter (the Letter) from the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the year ended December 31, 2021. [...]GlobeNewswire - US01 Apr 2022

Acer Therapeutics Regains Compliance with Nasdaq Listing StandardNEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that it has received notice from The Nasdaq Stock Market (Nasdaq) on March 30, 2022 informing Acer that it has regained compliance with the minimum market value of listed securities standard under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market, and the matter is now closed. [...]GlobeNewswire - US31 Mar 2022

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that, on March 21, 2022, it granted an option to purchase 1,704,328 shares of Jasper’s voting common stock (the “Option”) to Ronald Martell, Jasper’s newly appointed President and Chief Executive Officer. [...]GlobeNewswire - US25 Mar 2022

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., March 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 331,155 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 90,232 shares of common stock to nine newly hired team members. [...]GlobeNewswire - US18 Mar 2022

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain ComplianceROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”) would be delayed. [...]GlobeNewswire - US17 Mar 2022

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option to purchase an aggregate of 12,000 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee. [...]GlobeNewswire - US01 Mar 2022

American Rebel Holdings, Inc. Announces Pricing of $10.5 Million Public Offering and Nasdaq ListingNASHVILLE, TN , Feb. 04, 2022 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc., (NASDAQ:AREB)(NASDAQ:AREBW) (the “Company,” American Rebel,” “we,” “our” or “us”), a designer and marketer of branded safes and personal security, and self-defense products, announced today the pricing of its underwritten public offering of 2,530,121 units (the “Common Units”), at a price to the public of $4. [...]GlobeNewswire - US05 Feb 2022

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity’s common stock. [...]GlobeNewswire - US04 Feb 2022

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company’s common stock with an exercise price of $2. [...]GlobeNewswire - US07 Jan 2022

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 25 individuals hired by Sarepta in December 2021. [...]GlobeNewswire - US01 Jan 2022

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 109,250 shares of Baudax Bio’s common stock and restricted stock units covering 31,900 shares of Baudax Bio’s common stock to 14 newly-hired employees, with a grant date of December 29, 2021. [...]GlobeNewswire - US31 Dec 2021

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock. [...]GlobeNewswire - US10 Dec 2021

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees inducement options to purchase an aggregate of 84,000 shares of BioCryst common stock on November 30, 2021 as inducements material to each employee entering into employment with BioCryst. [...]GlobeNewswire - US03 Dec 2021

Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing RuleDAVIS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (Nasdaq: MBII) today announced that it has received a letter from the Listing Qualifications Department of the Nasdaq Capital Market notifying the company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company’s closing bid price being below $1. [...]GlobeNewswire - US08 Nov 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 17 individuals hired by Sarepta in October 2021. [...]GlobeNewswire - US29 Oct 2021

Staffing 360 Solutions Announces $9.25 Million Private Placement Priced At-The-Market Under Nasdaq RulesNEW YORK, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Staffing 360 Solutions, Inc. (NASDAQ: STAF), a staffing company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 4,683,547 shares of common stock (or common stock equivalents) in a private placement priced at-the-market under Nasdaq rules. [...]GlobeNewswire - US29 Oct 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Oct. 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 48,800 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 8,200 shares of common stock to three hired employees. [...]GlobeNewswire - US16 Oct 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 137,250 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 23,000 shares of common stock to seven hired employees. [...]GlobeNewswire - US17 Sep 2021

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 43,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. [...]GlobeNewswire - US03 Sep 2021

Greenlane Holdings Announces $32 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBOCA RATON, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. (“Greenlane” or the Company”) (Nasdaq: GNLN), a global house of brands and one of the largest sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 10,126,583 shares of the Company’s common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 6,075,950 shares of the Company’s common stock, at an effective purchase price of $3. [...]GlobeNewswire - US09 Aug 2021

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)TUCSON, Ariz., July 23, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that, on July 13th and July 22nd, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 30,000 shares of common stock to two employees who have recently joined HTG. [...]GlobeNewswire - US23 Jul 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 150,750 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 25,250 shares of common stock to seven new employees. [...]GlobeNewswire - US16 Jul 2021

MamaMancini’s Announces Uplisting to the Nasdaq Capital MarketCompany to Maintain Ticker Symbol “MMMB” and Begin Trading On Thursday, July 15thGlobeNewswire - US14 Jul 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Amanda Providakes in connection with her employment with the Company effective on July 6, 2021. [...]GlobeNewswire - US09 Jul 2021

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. [...]GlobeNewswire - US02 Jul 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3. [...]GlobeNewswire - US02 Jul 2021

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of July 1, 2021. [...]GlobeNewswire - US02 Jul 2021

Ocean Power Technologies Announces Planned Transfer of Nasdaq Listing to NYSE American Stock ExchangeMONROE TOWNSHIP, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (OPT or the Company) (NASDAQ: OPTT), a leader in innovative and cost-effective ocean energy solutions, announced today that it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. [...]GlobeNewswire - US08 Jun 2021

Health Assurance Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly ReportSAN FRANCISCO, June 04, 2021 (GLOBE NEWSWIRE) -- Health Assurance Acquisition Corp. (Nasdaq: HAACU) (the “Company”) today announced that, on May 28, 2021, it received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”). [...]GlobeNewswire - US05 Jun 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 28, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 6 individuals hired by Sarepta in May 2021. [...]GlobeNewswire - US28 May 2021

Stryve Foods LLC, an Emerging Healthy Snacking Platform, to list on NASDAQ through business combination with Andina Acquisition Corp. IIICombined company to focus on manufacturing and marketing highly differentiated healthy snacks that disrupt traditional snacking categoriesGlobeNewswire - US28 Jan 2021

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing StandardsThe Company’s Stock Will Continue to be Listed and Traded on The Nasdaq Stock MarketGlobeNewswire - US19 Jan 2021

Golden Minerals Regains Compliance with NYSE American Continued Listing StandardsGOLDEN, Colo., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Golden Minerals Company (NYSE American and TSX: AUMN) (“Golden Minerals”, “Golden” or “the Company”) announced today that it has received written notice from the NYSE American LLC (the “NYSE American”) that the Company has regained full compliance with the continued listing standards outlined in Part 10 of the NYSE American Company Guide (the Company Guide). [...]GlobeNewswire - US15 Jan 2021

Nasdaq to Advance Diversity through New Proposed Listing RequirementsStandardized disclosure framework to drive greater transparency on corporate governanceGlobeNewswire - US01 Dec 2020

Exela Receives Nasdaq Listing ExtensionIRVING, Texas, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (NASDAQ: XELA) (“Exela” or the “Company”) today announced that the Nasdaq Hearings Panel (the “Panel”) granted Exela’s request for an extension to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market (the “Rule”). [...]GlobeNewswire - US13 Oct 2020

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)BRIDGEWATER, N.J., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging, digital, and IoT products and platforms, today announced that the Company issued restricted stock and stock option awards to seven newly hired employees. [...]GlobeNewswire - US28 Aug 2020

Top Ships Inc. Announces Compliance With NASDAQ Minimum Bid Price RequirementATHENS, Greece, Aug. 25, 2020 (GLOBE NEWSWIRE) -- TOP Ships Inc. (Nasdaq:TOPS) (the “Company” or “TOPS”), announced today that NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement for the Nasdaq Capital Market, set forth in Nasdaq Listing Rule 5550(a)(2). [...]GlobeNewswire - US25 Aug 2020

Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on ListingPARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the delay in the filing of the Company’s Form 10-Q for the quarterly period ended June 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), Interpace does not currently satisfy Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of all periodic reports with the SEC. [...]GlobeNewswire - US20 Aug 2020

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23. [...]GlobeNewswire - US07 Aug 2020

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of August 3, 2020. [...]GlobeNewswire - US07 Aug 2020

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 20 individuals hired by Sarepta in July 2020. [...]GlobeNewswire - US31 Jul 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on July 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc. [...]GlobeNewswire - US31 Jul 2020

Marrone Bio Innovations Regains Compliance with Nasdaq Minimum Bid Price RequirementDAVIS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced that it received notice from The Nasdaq Stock Market, LLC (Nasdaq) on June 19, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. [...]GlobeNewswire - US22 Jun 2020

MicroVision Regains Nasdaq ComplianceREDMOND, Wash., June 22, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (Nasdaq:MVIS) announced that it has received a letter from Nasdaq confirming that it has regained compliance with Nasdaq’s listing requirements.GlobeNewswire - US22 Jun 2020

Digital Ally, Inc. Regains Compliance With Nasdaq Minimum Market Value of Listed Securities RequirementMarket Value of Listed Securities Exceeds $35 million at Closing for Ten Consecutive Trading DaysGlobeNewswire - US22 Jun 2020

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMONMOUTH JUNCTION, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Company’s common stock has been at $1. [...]GlobeNewswire - US11 Jun 2020

MicroVision Regains Compliance with Nasdaq Market Value Listing RequirementREDMOND, Wash., May 27, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (Nasdaq:MVIS) announced that it has received a letter from Nasdaq on May 26, 2020 confirming that as of May 22, 2020 the company has regained compliance with Nasdaq’s market value listing requirement.GlobeNewswire - US27 May 2020